Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic umbilical cord-derived mesenchymal stem cells (Seoul National University Hospital)
- Development stage
- Unknown
- Lead developer
- Seoul National University Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional
01
Overview
Allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) are an investigational cell therapy developed by Seoul National University Hospital for the treatment of rotator cuff disease, including partial-thickness tears. These cells are harvested from human umbilical cord tissue and are characterized by their high proliferative capacity and low immunogenicity. When administered via ultrasound-guided intralesional injection, these stem cells are intended to promote tendon healing and reduce inflammation through the secretion of various growth factors and anti-inflammatory cytokines (paracrine effect). This regenerative approach aims to improve clinical outcomes and structural integrity of the tendon in patients with rotator cuff disease without the need for invasive surgical intervention.
- Other names
- allogenic umbilical cord-derived mesenchymal stem cellsUC-MSCallogeneic umbilical cord-derived mesenchymal stem cells-Seoul National University Hospital-rotator cuff tear
Beyond the preview
Go deeper on allogeneic umbilical cord-derived mesenchymal stem cells (Seoul National University Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic umbilical cord-derived mesenchymal stem cells (Seoul National University Hospital).